JP2018506554A5 - - Google Patents

Download PDF

Info

Publication number
JP2018506554A5
JP2018506554A5 JP2017544867A JP2017544867A JP2018506554A5 JP 2018506554 A5 JP2018506554 A5 JP 2018506554A5 JP 2017544867 A JP2017544867 A JP 2017544867A JP 2017544867 A JP2017544867 A JP 2017544867A JP 2018506554 A5 JP2018506554 A5 JP 2018506554A5
Authority
JP
Japan
Prior art keywords
composition
less
water
particles
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017544867A
Other languages
English (en)
Other versions
JP2018506554A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IN2016/050068 external-priority patent/WO2016135754A1/en
Publication of JP2018506554A publication Critical patent/JP2018506554A/ja
Publication of JP2018506554A5 publication Critical patent/JP2018506554A5/ja
Ceased legal-status Critical Current

Links

Claims (8)

  1. i.粒子の90%が1000nm未満であるような粒度分布を有する、水溶性水感受性有効成分またはその薬学的に許容される塩のナノ粒子と、
    ii.1種以上の湿潤剤と、
    iii.少なくとも1種のゲル化剤と、
    iv.非水性液体ビヒクルと、
    を含むナノ粒子局所組成物であって、
    ここで、該組成物は水を含ま
    前記水溶性水感受性有効成分は、ミノサイクリンまたはその薬学的に許容される塩であり、
    前記1種以上の湿潤剤は、シクロメチコン−ジメチコンコポリオールポリマーであり、
    前記非水性液体ビヒクルは、シクロメチコンまたはシクロメチコンと鉱油の混合物を含み、
    さらに、前記局所組成物が、ゲルである、組成物。
  2. 前記ナノ粒子が、粒子の90%(D90)が1000nm未満であり、前記粒子の50%(D50)が800nm未満であるような粒度分布を有する、請求項に記載の組成物。
  3. 前記ナノ粒子が、粒子の90%(D90)が700nm未満であり、前記粒子の50%(D50)が500nm未満であり、前記粒子の10%(D10)が300nm未満であるような粒度分布を有する、請求項に記載の組成物。
  4. 前記水溶性水感受性有効成分がミノサイクリン塩酸塩であり、約0.01%w/w〜約15%w/wに及ぶ濃度で組成物中に存在する、請求項に記載の組成物。
  5. 前記湿潤剤が前記組成物の約0.5重量%〜20.0重量%に及ぶ濃度で存在する、請求項に記載の組成物。
  6. 浸透促進剤をさらに含む、請求項に記載の組成物。
  7. 前記浸透促進剤がミリスチン酸イソプロピルまたはオレイン酸から選択される、請求項に記載の組成物。
  8. ざ瘡、酒さ、膿痂疹、または細菌によって引き起こされる皮膚疾患の治療用の、局所施用による、請求項1に記載のナノ粒子局所組成物
JP2017544867A 2015-02-25 2016-02-25 ナノ粒子組成物 Ceased JP2018506554A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN623/MUM/2015 2015-02-25
IN623MU2015 2015-02-25
PCT/IN2016/050068 WO2016135754A1 (en) 2015-02-25 2016-02-25 Nanoparticulate composition

Publications (2)

Publication Number Publication Date
JP2018506554A JP2018506554A (ja) 2018-03-08
JP2018506554A5 true JP2018506554A5 (ja) 2019-05-16

Family

ID=56789380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017544867A Ceased JP2018506554A (ja) 2015-02-25 2016-02-25 ナノ粒子組成物

Country Status (6)

Country Link
US (1) US10512608B2 (ja)
EP (1) EP3261619A4 (ja)
JP (1) JP2018506554A (ja)
AU (1) AU2016224863A1 (ja)
CA (1) CA2977612A1 (ja)
WO (1) WO2016135754A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
AU2002239504A1 (en) * 2000-12-06 2002-06-18 Pharmacia Corporation Laboratory scale milling process
US20080220075A1 (en) 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP1551457A1 (en) * 2002-07-16 2005-07-13 Elan Pharma International Limited Liquid dosage compositions of stable nanoparticulate active agents
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20160158261A1 (en) 2002-10-25 2016-06-09 Foamix Pharmaceuticals Ltd. Antibiotic Kit and Composition and Uses Thereof
GB0403702D0 (en) 2004-02-19 2004-03-24 Boots Co Plc Skincare compositions
WO2012050591A1 (en) 2010-10-15 2012-04-19 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
US8920821B2 (en) * 2006-04-14 2014-12-30 Perrigo Israel Pharmaceuticals Ltd. Pharmaceutical compositions comprising silica microspheres
WO2008097850A1 (en) 2007-02-02 2008-08-14 Warner Chilcott Company, Inc. Tretracycline compositions for topical administration
US20080188446A1 (en) * 2007-02-02 2008-08-07 Warner Chilcott Company Inc. Tetracycline compositions for topical administration
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
CN105147608B (zh) 2008-06-26 2019-12-10 安特里奥公司 真皮递送
US8784852B2 (en) 2009-02-27 2014-07-22 Audrey Kunin Topical skin care composition
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
MX359879B (es) * 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
SG10201600332TA (en) 2011-01-19 2016-02-26 Lab Skin Care Inc Topical minocycline compositions and methods of using the same
PT106679B (pt) * 2012-11-27 2015-03-25 Hovione Farmaciencia Sa Formulações tópicas de tetraciclinas, sua preparação e usos
IN2013MU03646A (ja) 2013-11-20 2015-07-31 Lupin Ltd
BR112016017690A2 (pt) 2014-01-29 2017-08-08 Vyome Biosciences Pvt Ltd Tratamentos para acne resistente

Similar Documents

Publication Publication Date Title
JP2018506554A5 (ja)
Abd-Elsalam et al. Formulation and in vivo assessment of terconazole-loaded polymeric mixed micelles enriched with Cremophor EL as dual functioning mediator for augmenting physical stability and skin delivery
KR100990810B1 (ko) 안과용 약물 및 이과용 약물을 위한 담체로서 합성 무기 나노입자의 용도
JP2013513612A5 (ja)
Cunha et al. Delivery system for mefenamic acid based on the nanocarrier layered double hydroxide: Physicochemical characterization and evaluation of anti-inflammatory and antinociceptive potential
US11919770B2 (en) Nano-sulfur containing composition and application thereof
ES2815571T3 (es) Composiciones de silicato estabilizado y su uso como composiciones antitranspirantes
JP2009280627A5 (ja)
JP5740393B2 (ja) 皮膚および爪の真菌感染症の局所治療に適した組成物
EP2124878A1 (en) Increased effectiveness of allylamine drug compounds
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
CN103655459A (zh) 一种多功能微乳凝胶制剂及其制备工艺
JP2015502403A (ja) オーラル・ケア組成物
Ranneh et al. The use of surfactants to enhance the solubility and stability of the water-insoluble anticancer drug SN38 into liquid crystalline phase nanoparticles
Dong et al. Clay as a matrix former for spray drying of drug nanosuspensions
JP2006526026A (ja) 風邪及びインフルエンザ様症状の予防及び治療のためのキレート化亜鉛を含む組成物
Iannuccelli et al. Gastroretentive montmorillonite-tetracycline nanoclay for the treatment of Helicobacter pylori infection
US20220142914A1 (en) Suspension formulations of high load dispersions
TW201236697A (en) Oral and personal care compositions
JP2014534215A5 (ja)
WO2017024953A1 (zh) 尼莫地平水溶性衍生物及其制备方法和应用
CN107249574A (zh) 水凝胶组合物、其制备方法及其应用
MY150820A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2010023908A1 (ja) インドメタシン含有ナノカプセルおよびその製造方法
WO2015118885A1 (ja) 細菌性皮膚病用殺菌組成物